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Abstract
Zebrafish represent a vertebrate model organism that has been widely, and increasingly, employed over the last
decade in the study of developmental processes, wound healing, microbe-host interactions, and drug screening.
With the increase in the laboratory use of zebrafish, several advantages, such as a high genetic homology to
humans and transparent embryos, which allow clear disease evaluation, have greatly widened its use as a model for
studying tumor development in vivo. The use of zebrafish has been applied in several areas of cancer research,
mainly in the following domains: (1) establishing cancer models by carcinogenic chemical, genetic technology, and
xenotransplantation; (2) evaluating tumor angiogenesis; (3) studying tumor metastasis; and (4) anti-tumor drug
screening and drug toxicity evaluation. In this study, we provide a comprehensive overview of the role of zebrafish
in order to underline the advantages of using them as a model organism in cancer research. Several related
successful events are also reviewed.
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Introduction
Danio rerio, better known as zebrafish, have emerged as a
popular model for studying developmental processes and
human disorders. Zebrafish share a high level of genetic
and physiologic homology with humans, including brain,
digestive tract, musculature, vasculature, and an innate
immune system [1–6]. Moreover, approximately 70 % of
all human disease genes have functional homologs with
the species [7]. Zebrafish are prolific reproducers with the
potential to produce over 100 embryos per clutch. Their
extrauterine development is rapid; the major organs of the
zebrafish are fully developed by 24 hours post fertilization
(HPF), and they are ready for use in larvae experiments by
3 days post fertilization (DPF). Zebrafish larvae are trans-
parent during the early stages of life (through to 7 DPF),
and this phase can be extended to 9–14 DPF by the
addition of melanin synthesis inhibitor [8]. Zebrafish are
small in size and require inexpensive food. It is easy, there-
fore, to maintain thousands of larvae in a laboratory at a
reasonable cost.
Due to the advantages of genetic homology, physiology,
and developmental similarity, zebrafish have increasingly
become a desirable tool for studying the development and
modeling of human disease [9, 10]. In the transparent
embryo and larvae, clear time-lapse non-invasive
imaging and protein/cell marker tracking significantly
aid the observation of biological and disease processes
[11, 12]. Several types of gastrointestinal disorders,
such as inflammatory bowel disease, non-alcoholic fatty
liver disease (NAFLD), and alcoholic liver disease, can
be modeled in zebrafish [13–17]. Zebrafish have also
been used in the analysis of complex brain disorders
and muscle disease, including depression [18], autism
[19], psychoses [20], and muscular dystrophies [21]. In
addition, the ability to regenerate both fins and cardiac
tissue make zebrafish particularly suitable for studying
the wound healing response to various injuries [22].
Because of these advantages, zebrafish have proved to be
superior for use in cancer research over the last decade.
There are several long-standing methods for establishing a
cancer model in zebrafish, including carcinogenic treat-
ment, transgenic regulation, and the transplantation of
mammalian tumor cells [23]. By inducing different gene
mutations or activating signaling pathways through the
use of chemicals, tumors can be induced in a wide variety
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of organs in zebrafish, such as the liver, pancreas, intestinal
canal, skin, muscle, vasculature, and testis [24–28]. Trans-
genic technology enables the formation of specific types
of tumor by the overexpression of particular oncogenes.
The xenotransplantation of mammalian tumor cells
into zebrafish provides a novel way of studying the
interactions between the transplanted tumor cells and
the host’s vasculature. Zebrafish have also been
exploited for the investigation of tumor angiogenesis,
which represents a critical step in tumor progression
and is a target for anti-tumor therapies. The vascular
system in a zebrafish embryo bears a strong resem-
blance to that in humans, and rapidly forms a single
blood circulatory loop at 24 HPF. In zebrafish, the vas-
cular endothelial cells can be stained by a fluorescent
protein so that the neovascularization in the tumor
microenvironment can be observed in the earliest stage.
Tumor metastasis has also been modeled in zebrafish.
The fluorescent-stained tumor cells are highlighted in
the transparent zebrafish embryos and larvaes, so that
the process of metastasizing tumor cells can be accur-
ately tracked at the cellular level. The novel casper zeb-
rafish line, a generation of double pigmentation
mutant, even has a completely transparent body in
adulthood. This superior generation of zebrafish, in
conjunction with fluorescent imaging techniques, al-
lows the noninvasive tracing of stained tumor cells in
adult fishes [8]. It is worth mentioning that cancer stem
cells account for only a small fraction of tumor cells
and are too few in number to be feasibly transplanted
in a mammalian model in order to assess metastasis.
However, only a very small number of cancer stem cells
are required in zebrafish for this purpose because of
their small size. Additionally, the high fertility and low
maintenance costs of zebrafish makes them suitable for
the large-scale screen of antineoplastic drug efficacy
and toxicity.
This paper focuses attention on the wide application
of zebrafish as a superior model in cancer research, par-
ticularly with regard to establishing tumor models, and
studying angiogenesis, metastasis, and antineoplastic
drug screens.
Cancer model establishment in zebrafish
Neoplasia was rarely found in wild zebrafish. Using a
combination of chemical treatment, genetic technology,
and tumor cell xenotransplantation, the vast majority of
human tumors can be modeled in zebrafish [29]. Car-
cinogenic chemical treatment is commonly used in indu-
cing tumorigenesis. Several carcinogenic compounds are
able to induce canceration in a number of organs, such
as dimethylbenzanthracene (DMBA) [30], diethylnitrosa-
mine (DEN) [23], N-nitrosodimethylamine (NDMA)
[31], N-ethyl-N-nitrosourea (ENU) [24], and N-methyl-
N1-nitro-N-nitrosoguanidine (MNNG) [32]. The in-
duced tumors cover a wide spectrum of tumors found
not only in the digestive system (i.e. liver, pancreas, and
intestinal canal) but also in the skin, muscle, vasculature,
and testis [24–28]. As reported, exposure of the vhl+/−
zebrafish to DMBA revealed an increase in the occur-
rence of hepatic, bile duct, and intestinal tumorigenesis
at 2 months following treatment [33]. Exposure to DEN
results in different types of hepatocellular carcinomas,
hepatoblastomas, hepatoma, cholangiocarcinoma, and
pancreatic carcinoma in zebrafish [26]. Exposure of
zebrafish to NDMA for 2 months leads to cholangiolar
tumors (cholangiocarcinomas and cholangiomas) and
hepatocellular tumors (hepatocellular carcinomas and
adenomas) [31]. And exposure of zebrafish to ENU and
MNNG results in liver and testis tumorigenesis [24, 27].
A number of reverse genetic tools have been developed
for the study of gene functions in zebrafish. Morpholinos
are usually injected at the 1–4 cell stage of embryos to
provide transient knockdown of the target gene expression
[34]. Another targeted genome modification technology,
called TILLING (Targeting Induced Local Lesions IN Ge-
nomes), is highly dependent on large-scale traditional
post-transcriptional forward genetic screens expression
[35–38]. Moreover, engineered endonucleases, includ-
ing ZFNs (zinc finger nucleases), the CRISPR-Cas sys-
tem, and TALENs (transcription activator-like effector
nucleases), provide efficient strategies to disrupt site-
directed genes by inducing double strand breaks in the
target genes [39, 40].
Several types of tumor have been generated by indu-
cing mutants in known tumor suppressor genes. The
knockout p53 gene in zebrafish, for example, was found
to result in an increase of malignant peripheral nerve
sheath tumors (MPNST) [41]. In addition, the APC gene
mutant in zebrafish leads to colon adenoma initiation
and progression, suggesting an association with the ac-
tivation of the Wnt signaling pathway [42]. Several
other gene mutants were found to be related to differ-
ent types of tumors in zebrafish. As reported, mutants
in the NF1 gene lead to high-grade gliomas and
MPNSTs [43], those in BRCA2, mybl2, and espl1 lead
to testicular neoplasias [44, 45], those in the pen/lgl2,
bmyb and cds genes cause epidermal neoplasia [32, 46,
47], and GSTT1 deletion related to lymphoma prog-
ression [48], and vhl mutants lead to an increase in
hepatic and intestinal tumors [33]. The immune and
hematopoietic system in zebrafish is similar to that in
humans, which means that not only solid tumors but
also hematologic malignancies can be modeled [6]. The
most frequent mutant in the tumor suppressor pten in
zebrafish was related to an increasing morbidity of T-cell
acute lymphoblastic leukemia (T-ALL) and hemangiosar-
coma [49, 50].
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Through the transgenic expression of human or mouse
oncogenes, several cancer models have been established in
zebrafish. T cell acute lymphoblastic leukemia was the first
cancer induced by transgenic technology in zebrafish,
which was induced by the Myc transgenes [51]. Subse-
quently, overexpression of the oncogenes xmrk, Myc and
KRAS(V12)in zebrafish was found lead to hepatoma forma-
tion in both juvenile and adult transgenic fish [52–55].
Amplification of MYCN and fgf8 expressions markedly
promotes the formation of neuroblastoma [56]. Rhabdo-
myosarcoma has also been induced in zebrafish by using a
specific up-regulate oncogenic KRAS(G12D) expression
[57]. Overexpression of Akt1 enhances lipoma formation
[58]. In combination with the p53 mutant, overexpression
of some oncogenes in zebrafish leads to different tumor
phenotypes, such as scr (hepatoma) [59], NRAS (melan-
oma) [60], BRAF (melanoma) [41], and EWS-FIL1
(Ewing's sarcoma) [61]. Additionally, the co-activation of
the hedgehog and AKT pathways promotes tumorigenesis,
suggesting that a transgenic approach is a useful tool for
studying the interaction of oncogenes and oncogenic path-
ways in zebrafish [62].
Xenotransplantation represents a novel method to es-
tablish tumor models in zebrafish. One of the great
strengths of xenotransplantation is that the transplanted
tumor cells can be marked by fluorescent staining to en-
able them to be distinguished from normal cells in order
to allow clear observation of the development process of
the tumor [63]. The first human xenotransplant assays in
zebrafish began in 2005. By injecting 1 ~ 100 melanoma
cells into 3.5 ~ 4.5 HPF embryos, the migration in the de-
veloping larvae was clearly observed [64]. Transplantation
of different types of tumor cells in zebrafish was carried
out subsequent to this innovative work. Microinjecting gli-
oma stem cells into the embryonic yolk sac region in 2
DPF embryos resulted in an observable invasion in the
embryos via the vessels [65]. Hepatocellular carcinoma
(HCC) was also modeled for the identification of the cura-
tive effect of anti-cancer molecules [66]. Several other
types of tumor, such as lung cancer [67], pancreatic cancer
[68], ovarian carcinomas [69], breast cancer [70], prostate
cancer [71], retinoblastoma [72], and leukemia [73], have
also been transplanted in zebrafish.
All the methods and types of induced tumor are com-
bined in Table 1. The induced tumors are mainly located
in the digestive and reproductive systems, and then the
nervous system and epithelium.
Tumor angiogenesis in zebrafish
Angiogenesis is considered a key factor in tumor growth
and subsequent metastasis. Tumor vessels play an im-
portant role in transporting oxygen and nutrients to
support the growth of tumor cells. For this reason, the
capability of blood vessel formation within the tumor
not only determines the malignancy of the cancer but
also influences the therapeutic effects and prognosis.
Both in research evidence and clinically, angiogenesis in-
hibitors in combination with chemotherapy improved
the outcomes in cancer patients [74]. However, it is diffi-
cult to detect the original vascularization in traditional
mammalian models because such models only permit
the capture of static images, which probably relate to the
late stage of the tumor. The lack of observation at the
earliest stages of tumor formation means that the mech-
anism of vascularization is still not fully understood.
Human umbilical vein endothelial cells (HUVEC) are
widely used in the investigation of angiogenic mecha-
nisms in vitro. The system of angiogenesis can be eval-
uated by the cellular responses of HUVEC, such as cell
proliferation, cell cycle, tube formation, cell migration,
and cell adhesion to matrix proteins [75]. Several other
quantitative angiogenesis assays, for instance the matrix
implant assay and microcirculatory preparations such
as the chicken chorioallantoic membrane and corneal
micropocket assay, provide continuous monitoring of
the angiogenic response [76]. However, the physiological
status of angiogenesis may be quite different when trans-
lated to the area of cancer research. Indeed, angiogenesis
in the tumor microenvironment relys on a distinct signal-
ing pathway and displays large alterations in morphology
and function when compared with normal vasculogenesis.
Thus, in vitro research may be not suitable for modeling
angiogenesis in tumor organization.
Zebrafish provide an ideal in vivo model for the research
of tumor angiogenesis. The physiology and pathology of
tumor angiogenesis in zebrafish is similar to that in
humans because the tumor microenvironment in zebrafish
is strikingly similar [77]. Additionally, the zebrafish vascu-
lature grows rapidly (a single blood circulatory loop in
zebrafish is fully developed in 24 HPF) and the transparent
body allows for high-resolution in vivo non-invasive im-
aging [77]. The addition of PTU (a tyrosinae inhibitor
that prevents melanin synthesis) to water can lengthen
the transparency of the larvae to 9–14 DPF [78].This
years, a pigmentation mutant casper line with a com-
pletely transparent body has allowed the non-invasive
imaging of the vasculature across the whole body [8].
Real-time observation of vessels in larvae can be
achieved after microinjection of chemical dyes into the
vascular system [79]. Additionally, taking advantage of
the Tg(flk1: EGFP) zebrafish, a transgenic fish line with
a green fluorescent protein tissue-specific expression in
the vasculature, individual cell growth and vessel for-
mation can be easily detected under confocal micros-
copy [80]. In red fluorescent tumor tissues, the green
fluorescent protein marked neovascularization is high
lighted and enables the observation of angiogenesis in
the initial stages.
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Gene identification plays a key role in the exploration of
angiogenesis and in discovering novel therapeutic targets
for anti-angiogenesis drugs. Zebrafish are compliant to
genetic manipulation at low cost and within a short time.
In this manner, a number of signaling pathways for angio-
genesis and various targets for drug treatment have been
identified over the past few years. Targeted gene knock-
down of TNFRSF1B in zebrafish was found to promote
the apoptotic program, and knockdown of TNFRSF1A, or
up-regulation of NF-κB, prevented endothelial cell apop-
tosis, suggesting that TNFRSF1A and TNFRSF1B were
involved in the signaling pathways of angiogenesis [81]. In
another study, a silencing of LIM kinases in pancreatic
cancer tissues resulted in a decrease of angiogenesis in
zebrafish [82]. These data suggest new therapeutic targets
for the control of the tumor-driven angiogenesis process.
Compared with other angiogenesis models such as the
chorioallantoic membrane of the chicken embryo, zebra-
fish show their superiority with regard to modeling the
in vivo environment, compliance in genetic manipula-
tion, and allowing clear observation of the interaction
between tumor cells and neonatal micrangium.
Tumor metastasis in zebrafish
The large amount of evidence from various studies has
clarified that metastasis is a dynamic, complex, and
multi-step process that includes tumor cells penetrating
into the circulatory system, spreading to distant tissues,
engrafting in the parenchyma, and developing in the
graft area [83]. An insight into the mechanism of tumor
metastasis is conducive to the discovery of anti-tumor
drugs and the improvement of clinical treatments. Much
of the previous analysis of metastasis conducted in in
vitro cell systems had obvious weaknesses because the
complete metastasis process cannot be abstracted away
from the in vivo environment and vascular system. In
vivo mouse models also have significant disadvantages:
1) it is difficult to evaluate the early stage of metastasis;
2) the complete process of metastasis in a mouse re-
quires a long period of time; 3) real-time imaging of mi-
nute tumor lesions in deep tissues is impossible without
termination and autopsy; 4) immunodeficiency mice
may still have a residual anti-tumor competence that
can prevent tumor cell metastasis [84]; 5) mice require
feeding at high cost throughout the experiment.
Table 1 Summary of the methods used and the types of tumor induced in zebrafish
Technology Treatment Types of induced tumor Reference
Chemical treatment DMBA hepatoma, cholangiocarcinoma and intestinal cancer [30]
DEN hepatoma, cholangiocarcinoma and pancreatic carcinoma [23]
NDMA hepatoma and cholangiocarcinoma [31]
ENU hepatoma and testicular cancer [24]
MNNG hepatoma and testicular cancer [32]
Genetic technology
Knockout: P53 malignant peripheral nerve sheath tumors [41]
APC colon adenoma [42]
NF1 gliomas and malignant peripheral nerve sheath tumors [43]
BRCA2, MYBL2, esp11 testicular cancer [44, 45]
pen/lgl2, bmyb and cds gene epidermal cancer [32, 46, 47]
GSTT1 lymphoma [48]
vhl hepatoma and intestinal cancer [33]
pten T-cell acute lymphoblastic leukemia and hemangiosarcoma [49, 50]
Overexpression: Myc T-cell leukemia and hepatoma [51, 53]
xmrk and KRAS(V12) hepatoma [52, 54, 55]
MYCN and fgf8 neuroblastoma [56]
KRAS(G12D) rhabdomyosarcoma [57]
Akt1 lipoma [58]
Scr in p53 mutant background hepatoma [59]
NRAS, BRAF in p53 mutant background melanoma [60, 41]
EWS-FIL1 in p53 mutant background Ewing's sarcoma [61]
Xenotransplantation Transplant tumor cells in zebrafish Melanoma, glioma, hepatoma, lung cancer, pancreatic cancer, ovarian
carcinomas, breast cancer, prostate cancer, retinoblastoma, leukemia
[64–73]
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The cancer model of zebrafish overcomes the drawbacks
of murine xenograft models and shows several exceptional
strengths. The adaptive immune system in zebrafish larvae
is not completely developed until 14 DPF so that most
transplanted cancer cells can survive and metastasize [85].
The transparent body of zebrafish enables the clear ob-
servation of tumor metastasis under the microscope. In
the transparent casper line, the dynamic and spatial
characteristics of micrometastases can be real-time im-
aged at the single cell level [8]. In order to highlight
metastasis in zebrafish, tumor cells can be stained by a
chemical dyestuff (such as CM-Dil) or labeled by red
fluorescent protein (RFP) [86]. By injecting red fluores-
cent mammalian tumor cells into the Tg(fli1: EGFP)
transgenic zebrafish, in which vascular endothelial cells
are labeled by green fluorescent protein, both the
process of tumor cell metastasis and changes in the
vascular system can be clearly seen throughout the
body. In addition, cancer stem cells are too few in
number to be transplanted in mammalian models but
zebrafish are small enough for such xenografting, and
the rapid progress of metastasis in zebrafish is able to
be observed within 2 days after injection [65].
Zebrafish provide an experimentally tractable animal
model for the identification of suppressing or promot-
ing factors in metastasis. By transplanting RFP express-
ing U87 glioma stem cells (GSCs) into the yolk sac of
Tg(fli1:EGFP)y1 zebrafish embryos, the different inva-
sive stages of GSCs, such as approaching, clustering, in-
vading, migrating, and transmigrating, can be clearly
observed at 2 days post-injection [65]. In this experi-
ment, invasive GSCs were found to have MMP-9 high
expression in common and treatment with the MMP-9
inhibitor significantly decreased the percentage of inva-
sive cells in the embryos [65]. In an experiment on hyp-
oxia, DiI-labeled tumor cells were injected into the
perivitelline space of 48 HPF embryos, which were
subsequently placed in hypoxic water for 3 days. A sig-
nificant increase in metastasis and angiogenesis was de-
tected using a fluorescent microscope at the single-cell
level [87, 88]. Tumor cells and immune cells have been
co-implanted in the same zebrafish to investigate the
interactions in the tumor microenvironment [89]. The
co-implanting of DiI-labeled tumor cells and DiD-
labeled tumor-associated macrophages (TAM) relates
to an increase in metastasis in zebrafish, and their asso-
ciation could be detected in overlapping colors [89].
The signaling pathway for metastasis has been evaluated
in the zebrafish model. The technology of target knock-
down of proteins involved in the signaling pathway with
chemical inhibition or small interfering RNA is not new in
zebrafish. The TGF-beta signaling pathway was found to
control human breast cancer metastasis in zebrafish. After
treatment with the TGF-beta signaling pathway inhibitor,
the invasion and metastasis processes in zebrafish were
inhibited significantly [70, 90].
Drug screening in zebrafish
The effects of molecule antineoplastic drugs have often
been detected by biochemical assays or in cell line models,
but the outcomes were unsatisfactory. Because of a lack of
a complete biologic context in the screening process, the
identified active compounds were often ineffective when
applied in a vertebrate model. At this point, a whole animal
screen sheds valuable information on anti-tumor effects,
organ toxicity, and pharmacokinetic data based on the
entire organism [91]. However, mice are fiscally prohibi-
tive for large-scale screen. Zebrafish, on the other hand,
have emerged as a powerful platform for use in high-
throughput antineoplastic drug screening on the strength
of the following advantages. A pair of zebrafish produce
hundreds of embryos a week, and larvae have a small size
that can be arrayed in a 96-well plate, which greatly de-
creases the cost of maintaining them in the laboratory.
Drug treatments can be easily achieved by merely adding
the medicine to the aqueous environment. In addition, the
transparent zebrafish body enables the real-time non-
invasive imaging of anti-tumor effects and drug toxicity.
Most types of cancer can be modeled in zebrafish, thus
zebrafish can be used to assess the anti-tumor effects of
chemotherapeutic drugs. The growth of tumor cells and
degree of invasion are the main concerned outcomes.
Over the past 5 years, several large chemical screens have
been performed in zebrafish. The anti-melanoma chemical
genetic screen is one of the best representations. To our
knowledge, the propagation of melanoma is critically re-
lated to the neural crest lineage. 2,000 chemicals were
screened to identify inhibitors of the neural crest lineage
in zebrafish embryos, and the selected chemicals were
tested for effects in melanoma. Leflunomide, an inhibitor
of dihydroorotate dehydrogenase, was found to inhibit the
development of both neural crest and human melanoma.
This screen shed light on the important role of zebrafish
in antineoplastic drug discovery [92].
An anti-leukemia compound screen was performed in
zebrafish in 2012. Zebrafish show a striking similarity in
the hematopoietic system development with humans,
and almost all human adult blood lineages have corre-
sponding homologous cell lines in zebrafish. For this
reason, effective hematopoietic drugs in zebrafish may
serve the same function in humans. More than 25,000
small compounds were identified in this drug screen and,
finally, a compound called lenaldekar (LDK) was found to
be able to induce long-term remission in adult zebrafish
with T-cell acute lymphoblastic leukemia (T-ALL). A sub-
sequent study showed that LDK had a generalized anti-
leukemia effect not only to T-ALL but also to several
diverse leukemias such as B-ALL and CML [93, 94].
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Anti-angiogenesis drugs have been screened in zebrafish.
Following a screen of 288 new compounds, two kinase in-
hibitor compounds were found to have anti-angiogenic
properties and a phosphorylase kinase subunit G1 (PhKG1)
was identified as the kinase target [95]. In a similar way,
rosuvastatin was identified as inhibiting the angiogenesis in
developing zebrafish embryos [96]. Anti-lymphatic drug
compounds were also identified in zebrafish. Four com-
pounds previously used in humans were found to have
anti-lymphatic activity in zebrafish [97]. These studies dem-
onstrate that zebrafish provide an effective utility platform
for large-scale antineoplastic drug screens and medicine ef-
ficacy detection.
Zebrafish have been used to identify compounds that
work in the genetic signaling pathways of carcinogenesis.
The bmyb gene is important for controlling the mitotic
checkpoint and is connected with cancer susceptibility
[32]. In order to identify the drug function of small
molecules in the bmyb pathway, 16,000 compounds
were tested. A compound named persynthamide was
noted to have an inhibiting effect in bmyb-dependent
mitotic defects and reduced the incidence of tumors in
zebrafish [39].
Antineoplastic drug toxicity can be observed over a
short period because of the rapid development of zeb-
rafish. In a screen for detecting the inner ear hair cell
toxicity of anti-tumor drugs, 13 out of 88 anti-tumor
drugs, and 5 out of 10 drug combinations, were authenti-
cated ototoxic. In addition, dose–response studies were
performed on these detected drugs [98]. Several outcomes
were usually detected to assess the toxic effect of antineo-
plastic drugs, such as cell damage, development process,
and vitality. Drug toxicity screening has an important
significance in selecting the appropriate therapy in clinical
cancer treatments.
Discussion
Considering the past two decades, it is easy to see that
enormous progress has taken place with regard to zeb-
rafish in terms of modeling human cancers. The wide
use of zebrafish sheds greater light on the investigation
of gene functions, tumor angiogenesis, tumor metasta-
sis, and the discovery of antineoplastic drugs in cancer
research (Fig. 1).
Several problems often trouble cancer researchers.
Traditionally, the murine system is the most utilized ani-
mal system for studying human cancers. However, the
long gestation time greatly lengthens the experimental
procedure. In addition, real-time imaging of minute
tumor lesions in deep tissues is difficult in a murine
system unless autopsy is performed. The high cost of a
murine system also rejects the high-throughput screen-
ing of drug discoveries.
There is no doubt that zebrafish will play an increasingly
significant role in cancer research. Zebrafish have several
prominent advantages in modeling human cancers, such
as rapid development, a transparent body, high genetic
homology, and ease of genetic manipulation. These unique
advantages enable primary studies to be assumed before
further verification using costly murine systems. Indeed,
the ease of establishing a cancer model and the real-time
observation of tumor progression in zebrafish greatly im-
proves the efficiency of the experiment. Zebrafish provide
a good model for researching the mechanisms of tumor
angiogenesis and metastasis because the newly-formed
vessels and metastatic tumor cells can be clearly marked
and real-time observed through the transparent body.
Additionally, the high reproductive rate and low financial
cost of zebrafish enables high-throughput screening of
anti-tumor drugs.
However, as an underdeveloped model organism, several
weaknesses limit the application of zebrafish in the re-
search community. Only a few versatile tools and validated
reagents are suitable for use in zebrafish, in comparison
with traditional mammalian models. This prevents us
from exploring the details of the molecular and cellular
mechanisms involved in cancer development. Zebrafish
also have many duplicate genes that significantly compli-
cate genetic manipulation. Forward genetic manipulation
is not able to completely knock out both copies of the tar-
get genes, and any gene copies remaining will render the
phenotype unchanged. CRISPR, a newly developed reverse
genetic technology, shows its superiority to overcome this
difficulty, as it has the property to remove multiple genes
thereby reveal phenotypes [99]. In addition, it is difficult
to give some water-insoluble drugs to zebrafish because
the carrier solvents may be toxic before the drugs dis-
solve. Moreover, the embryos need to be raised in water
maintained at 28 °C, and this temperature may not be
optimum for the metabolism of mammalian tumor cells
Fig. 1 The main fields of application of zebrafish in cancer research
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(which require 37 °C). Therefore, raising the incubation
temperature to 34 °C may offer an effective compromise.
As previously reported, maintaining embryos with trans-
planted tumor cells in 34 °C water did not affect the vital-
ity of the embryos or the growth of tumor cells [100].
This paper systematically expounds the significance of
zebrafish within the field of cancer research. It is a com-
prehensive summary of the various uses of zebrafish
within the field and forecasts a more extensive application
of them in the future. Tumor immunotherapy represents
a new prevailing therapy in the clinical treatment of tu-
mors. Zebrafish share a similar immune system with
humans, so there is, therefore, the prospect of them being
used to research the curative effects of tumor immuno-
therapy. Several other areas, such as tumor recurrence
and circulating tumor cells research, will also require a
zebrafish model for further exploration of the mechanism
and physiologic processes.
In conclusion, zebrafish are increasingly becoming a
superior vertebrate model for cancer research and can
be expected to provide further contributions to our
deeper understanding of the mechanisms of genetic
function, angiogenesis, metastasis, and antineoplastic
drug screening in the near future.
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